Vanguard Group’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $706K | Sell |
593,247
-81,543
| -12% | -$97K | ﹤0.01% | 3845 |
|
|
2025
Q1 | $1.37M | Buy |
674,790
+3,165
| +0.5% | +$6.43K | ﹤0.01% | 3612 |
|
|
2024
Q4 | $4.04M | Buy |
671,625
+34,087
| +5% | +$205K | ﹤0.01% | 3351 |
|
|
2024
Q3 | $4.46M | Sell |
637,538
-107,972
| -14% | -$756K | ﹤0.01% | 3305 |
|
|
2024
Q2 | $4.32M | Buy |
745,510
+238,325
| +47% | +$1.38M | ﹤0.01% | 3316 |
|
|
2024
Q1 | $3.63M | Buy |
507,185
+31,208
| +7% | +$223K | ﹤0.01% | 3413 |
|
|
2023
Q4 | $2.34M | Buy |
475,977
+7,570
| +2% | +$37.2K | ﹤0.01% | 3549 |
|
|
2023
Q3 | $4.48M | Buy |
468,407
+65,132
| +16% | +$623K | ﹤0.01% | 3298 |
|
|
2023
Q2 | $5.23M | Sell |
403,275
-5,940
| -1% | -$77K | ﹤0.01% | 3274 |
|
|
2023
Q1 | $5.19M | Buy |
+409,215
| New | +$5.19M | ﹤0.01% | 3292 |
|